Radient Pharmaceuticals Corp. (RPC) Announces Updated European Union Certification for Onko-Sure®

QualityStocks would like to highlight Radient Pharmaceuticals Corporation (AMEX: RPC) is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, such as diagnostic tests that assist physicians in answering important clinical questions related to early disease detection, including its Onko-Sure® In Vitro Diagnostic (IVD) cancer test.

In the company’s news yesterday,

Radient Pharmaceuticals Corp. announced that it has received CE-Mark approval from the European Union (EU) for the use of its Onko-Sure® In Vitro diagnostic (IVD) cancer test as a pan tumor marker for cancer. The company’s new CE-Mark Certificate for Onko-Sure® provides product access to 27 countries with a combined population of approximately 500 million.

A simple, non-invasive, patent-pending and regulatory-approved test, Onko-Sure® is used to detect, screen and monitor various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

“The new CE Mark approval for Onko-Sure® in Europe is a significant accomplishment that validates the impressive results that have been observed with this test,” stated Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. “RPC’s Onko-Sure® IVD cancer test has the potential to change the way cancer patients are diagnosed, monitored and treated.”

CE-Mark Certification clears the Onko-Sure cancer test kit for import and use in 27 countries including founding member states like the UK, Germany, and France, along with potential members like Turkey. According to the company, this new and product-specific CE-mark certification will also assist in their continuing efforts to expand the usage of Onko-Sure in key emerging markets like Asia, Latin America, Russia, and the Middle East.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.